Ribupatide record · updated 16h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only

All 2 studies Jump to the evidence Compare

What is Ribupatide used for?

Research peptide discovered via AI researcher. research peptide

How it works: GLP-1/GIP receptor agonist

Primarily researched for · Metabolic & appetite

Development stage

where Ribupatide sits between preclinical work and regulatory approval

1Cleared
Preclinical
Animal / in-vitro work
2Current
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 12 registered trials. It describes the research record, not a recommendation.

Identity

NameRibupatide

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMetabolic

Research levelEmerging

Discovered byThe Librarian · 2026

Pharmacology

MechanismGLP-1/GIP receptor agonist

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence0.70

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 23, 2026. How this works →

Research stats

Total studies2

Human / animal / cellular0 / 0 / 0

Highest trial phasePhase 1

Years covered2023–2026

Latest study1mo ago

Publication history

20232026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 2 Semantic Scholar UniProt

Study register

2 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist. FindingMean weight change in ribupatide groups ranged from -4.3 kg (-6.7%) to -7.7 kg (-9.6%), compared with -1.2 kg (-1.4%) in the placebo group.	review	2023	Full text read0.80
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist. FindingMean weight change in ribupatide groups ranged from -4.3 kg (-6.7%) to -7.7 kg (-9.6%) after four weekly doses, compared with -1.2 kg (-1.4%) in the placebo group.	review	2026	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Ribupatide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Ribupatide is discussed should be drawn from it.